Is There Now an Opportunity in Daiichi Sankyo After the Recent Share Price Slump?

• Whether you are wondering if Daiichi Sankyo Company is starting to look like good value after a rough stretch, or if the market still sees more downside ahead, this breakdown will help you sort signal from noise.
• The stock is down 7.8% over the last week, 2.9% over the last month, and a steep 26.2% over the past year, even though long term holders over 5 years are still sitting on a 10.7% gain.
• Recent headlines have focused on Daiichi Sankyo's expanding oncology portfolio and major global partnerships, which have sharpened investor attention on its long term growth runway. At the same time, regulatory and competitive pressures in pharmaceuticals have kept sentiment cautious, which helps explain why price moves have been so volatile.
• Right now, the company scores 4/6 on our valuation checks, suggesting pockets of undervaluation that traditional multiples might be missing. In the sections ahead we unpack those methods, then finish with an additional way to think about what this business is really worth.

Find out why Daiichi Sankyo Company's -26.2% return over the last year is lagging behind its peers.

Approach 1: Daiichi Sankyo Company Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a company is worth by projecting the cash it can generate in the future and discounting those cash flows back to today.

For Daiichi Sankyo Company, the latest twelve month free cash flow is negative at about ¥61.4 billion, reflecting investment activity and uneven cash generation. Analysts then expect cash flows to turn positive, rising to around ¥394.8 billion in 2026 and reaching roughly ¥444.4 billion by 2030. Beyond the initial analyst window, Simply Wall St extrapolates further annual growth to build a full 2 Stage Free Cash Flow to Equity model.

When all these projected cash flows are discounted back to today, the intrinsic value is estimated at about ¥6,544 per share. Compared with the current market price, this implies roughly a 45.6% discount, indicating that the market is assigning a cautious valuation relative to these long term cash flow projections.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Daiichi Sankyo Company is undervalued by 45.6%. Track this in your watchlist or portfolio, or discover 919 more undervalued stocks based on cash flows.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Daiichi Sankyo Company.

Approach 2: Daiichi Sankyo Company Price vs Earnings

For profitable businesses like Daiichi Sankyo Company, the price to earnings, or PE, ratio is a practical way to gauge whether investors are paying a reasonable price for each unit of earnings. In general, faster growth and lower perceived risk justify a higher PE, while slower or more uncertain earnings typically warrant a lower multiple.

Daiichi Sankyo currently trades on a PE of about 23.6x, which is above the broader Pharmaceuticals industry average of roughly 15.8x and also higher than its peer group average of around 21.6x. On those simple comparisons alone, the stock can look a bit expensive. However, these benchmarks do not fully capture company specific factors such as Daiichi Sankyo's growth outlook, margin profile, scale, and risk characteristics.

To address that, Simply Wall St uses a proprietary Fair Ratio, which estimates what a justified PE should be once growth, profitability, industry, market cap, and risk are all taken into account. For Daiichi Sankyo, this Fair Ratio is 29.7x, comfortably above the current 23.6x, suggesting the shares trade at a discount to what its fundamentals might warrant rather than at a premium.

Result: UNDERVALUED

PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1439 companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your Daiichi Sankyo Company Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple framework that lets you attach a clear story to your numbers, from your assumptions about future revenue, earnings and margins through to the fair value you think Daiichi Sankyo Company is really worth.

A Narrative on Simply Wall St connects three pieces: the business story you believe, the financial forecast that flows from that story, and the fair value that drops out of those forecasts, all in one place on the Community page used by millions of investors.

Because your Narrative shows a Fair Value next to the live market Price, it becomes a straightforward tool to help you compare when Daiichi Sankyo appears attractively priced, when it seems stretched, and when it might be time to reduce or close a position.

Narratives also update dynamically as new information such as trial results, regulatory decisions or earnings releases arrive, so your view stays current without you needing to rebuild everything from scratch. You can easily compare, for example, a bullish Daiichi Sankyo Narrative that targets around ¥6,800 with a much more cautious one closer to ¥4,500 to see which set of assumptions you find more convincing.

Do you think there's more to the story for Daiichi Sankyo Company? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com